Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Myelofibrosis

NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No Longer Available

N/A

Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation

Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)

Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis

01/15

NCT06371573: Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms

Completed

N/A

Europe

ULTRASOUND EXAM AND MRI SCAN

Federico II University

Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic/Early Primary Myelofibrosis

01/24

03/24

NCT02530619: Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

Active, not recruiting

N/A

Alisertib, Aurora A Kinase Inhibitor MLN8237, MLN-8237, MLN8237, Laboratory Biomarker Analysis, Pharmacological Study

Northwestern University, The Leukemia and Lymphoma Society, Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI)

Acute Megakaryoblastic Leukemia, Myelofibrosis, Primary Myelofibrosis

05/18

05/22

S-HEMO, NCT02260739: Sequential Analysis in Patients With an Hemopathy

Recruiting

N/A

246

Europe

Blood samples

Gustave Roussy, Cancer Campus, Grand Paris

Hemopathy

01/19

01/26

NCT03906344: Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

No Longer Available

N/A

INCB052793

Incyte Corporation

NCT03723148: Individual Patient Compassionate Use of Fedratinib

Available

N/A

Oral Fedratinib, FEDR

Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Myelofibrosis

NCT04526223: Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

Recruiting

N/A

RoW

comprehensive treatment regimen

xuna

Time of Hematopoietic Reconstruction

12/22

ChiCTR2000035444: Efficacy and Safety of Low-dose Ruxoltinib Combined with Thalidomide, Prednisone, and Testosterone Decanoate (TPT) in Patients with Lower and Intermediate Risk Myelofibrosis ---a Single Arm, Multicenter, and Prospective Study

Not yet recruiting

N/A

Low-dose Ruxoltinib Combined with Thalidomide, Prednisone, and Testosterone Decanoate (TPT)

The Sixth People's Hospital Affiliated to Shanghai Jiaotong University; Renji Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, Self-financing

Myelofibrosis

NCT03592576: Expanded Access to Navitoclax

No Longer Available

N/A

Navitoclax, ABT-263, Venetoclax, Venclexta, ABT-199, GDC-0199

AbbVie

Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma

CALRSUIVI, NCT04942080: Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes

Recruiting

N/A

260

Europe

CALR allele burden quantification

University Hospital, Angers, Ligue contre le cancer, France

Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage

04/23

04/26

RAMP, NCT06078319: Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera

Completed

N/A

189

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Adherence, Patient, Adherence, Treatment

06/23

NCT04745637: Managed Access Programs for INC424, Ruxolitinib

Available

N/A

Ruxolitinib, INC424

Novartis Pharmaceuticals

Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness, Polycythemia Vera (PV), Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD), Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

NCT05582083: Managed Access Program for Momelotinib in Myelofibrosis

No Longer Available

N/A

Momelotinib, GSK3070785

GlaxoSmithKline

Myelofibrosis, Primary Myelofibrosis

NCT06164561: 18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.

Recruiting

N/A

RoW

First Affiliated Hospital of Zhejiang University, Zhejiang Provincial Tongde Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, First People's Hospital of Hangzhou, Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University

Myelofibrosis

12/25

NCT06151119: 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

Recruiting

N/A

RoW

68Ga FAPI PET/CT

The First Affiliated Hospital of Xiamen University

Primary Myelofibrosis

10/24

06/25

METER, NCT05444972: A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Completed

N/A

998

Europe, Canada, US, RoW

AbbVie

Myelofibrosis

11/23

NCT04666025: SARS-CoV-2 Donor-Recipient Immunity Transfer

Completed

N/A

Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review, Questionnaire Administration

City of Hope Medical Center, National Cancer Institute (NCI)

Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma

05/23

NCT05972577: Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Active, not recruiting

N/A

Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration

Ohio State University Comprehensive Cancer Center

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma

12/23

12/24

BioScoreSMP, NCT03869476: Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.

Recruiting

N/A

130

Europe

Non-invasive diagnosis score

University Hospital, Angers

Myeloproliferative Disorder, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage

01/24

FIBROMOELLE, NCT06177366: A New Blood Score for Myelofibrosis Staging

Not yet recruiting

N/A

120

Blood sampling

Assistance Publique - Hôpitaux de Paris

Myeloproliferative Neoplasm

02/26

PHEMOP, NCT06361641: Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

Recruiting

N/A

Europe

Monocytes signatures in myeloproliferative neoplasms at diagnosis

University Hospital, Angers

Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis

10/25

10/27

EpiC, NCT06022328: Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms

Recruiting

N/A

120

Europe

Assessment of the epigenetic age

University Hospital, Bordeaux

Myeloproliferative Neoplasm

12/24

NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Recruiting

N/A

200

Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Total Body Irradiation, Cyclosporine A, CSA, Mycophenylate mofetil, MMF, Umbilical cord blood, UCB

Masonic Cancer Center, University of Minnesota

Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma

10/24

10/25

NCT03452774: SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Recruiting

N/A

50000

Clinical Trial Matching

Massive Bio, Inc.

Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes

12/26

06/27

CLONEMF, NCT05710211: Clonal Architecture of ASXL1-mutated Myelofibrosis

Not yet recruiting

N/A

Europe

Clonal architecture determination

University Hospital, Angers

Myelofibrosis

03/25

03/29

NCT05762874: Ruxolitinib in Patients With Myelofibrosis

Not yet recruiting

N/A

Ruxolitinib

Assiut University

Myelofibrosis

03/25

06/25

NCT01758042: Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

Recruiting

N/A

Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia

07/25

07/27

ALLO-BAT, NCT04217356: Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

Recruiting

N/A

Canada

Hematopoietic stem cell transplant, Ruxolitinib, JAKAVI, Hydroxyurea

University Health Network, Toronto

Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer

08/25

02/26

OBENE, NCT02897297: Myeloproliferative Neoplastic Diseases Observatory From Brest

Recruiting

N/A

1000

Europe

University Hospital, Brest

Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis

09/25

REALFed, NCT05883904: Real World Evidence of Fedratinib Effectiveness in MF

Recruiting

N/A

Europe

Fedratinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

01/26

TeleSICP, NCT05875805: A Telehealth Advance Care Planning Intervention

Not yet recruiting

N/A

207

Telehealth Serious Illness Care Program, Education Control

University of Rochester

Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis

09/25

12/25

NCT02760238: Myeloproliferative Neoplasms (MPNs) Patient Registry

Recruiting

N/A

5000

Canada

Observational

University Health Network, Toronto

Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myelomonocytic, Juvenile, Chronic Eosinophilic Leukemia-not Otherwise Specified, Myelodysplastic-Myeloproliferative Diseases, Neoplasms, Leukemia, Myelomonocytic, Chronic

10/25

NCT05882773: Asian Myeloproliferative Neoplasm (MPN) Registry

Recruiting

N/A

1000

RoW

The University of Hong Kong, Novartis

Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage

05/26

12/26

NCT02934477: Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Recruiting

N/A

650

Hematopoietic Stem Cell Transplant

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, National Institutes of Health (NIH), National Cancer Institute (NCI)

Myelofibrosis

11/26

10/27

NCT01973881: Quantitative MRI for Myelofibrosis

Recruiting

N/A

192

T1 Weighted MRI (magnetic resonance imaging)

University of Michigan, Sanofi, National Cancer Institute (NCI)

Myelofibrosis

12/26

NCT06073847: A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Recruiting

N/A

137

RoW

Fedratinib

Bristol-Myers Squibb

Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

12/27

AZA-MDS-006, NCT01688011: Connect® Myeloid Disease Registry

Recruiting

N/A

2300

Luspatercept

Celgene

Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

03/31

eTHEMA, NCT05326919: The Patient Cohort of the National Center for Precision Medicine in Leukemia

Recruiting

N/A

3000

Europe

Biobanking

Assistance Publique - Hôpitaux de Paris

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease, Myeloproliferative Neoplasm, Unclassifiable

03/42



	Diseases Companies Products Productz Mechanisms of Action Sites